Skip to search formSkip to main contentSkip to account menu

REV 2871

Known as: REV-2871 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

2-ethoxyethyl 5-chlorobenzoxazole-2-carboxylateEclazolast

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
Mechanism of action of the nonlipophilic antiallergic drug eclazolast (REV 2871) in the inhibition of mediator release in a mast cell model
Abstract.Objective and Design: In this study, we compared eclazolast with other lipophilic antiallergic drugs, relating to… 
1987
1987
REV 2871 (CHBZ): a potent antiallergic agent with a novel mechanism of action. I. Activity profile as an inhibitor of mediator release.
1986
1986
REV 2871 (CHBZ): A novel inhibitor of histamine release
CHBZ is a novel, non-disodium cromoglycate (DSCG)-like, antiallergic drugin vitro. Whereas DSCG loses anti-secretory activity… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)